Are there any subsets of patients where you would consider first-line dacomitinib for EGFR mutations positive NSCLC?

I continue to favor osimertinib as front line therapy for patients with EGFR mutation positive NSCLC. A retrospective analysis of response and benefit of osimertinib in some less common EGFR mutations was published, including G719X, L861Q, and S768I. The analysis showed clinical benefit with osimert...